Select Language

Fusion glycoprotein F0

Fusion glycoprotein F0 Overview

English Name	Respiratory syncytial virus F protein	Approved Drugs	3
Drugs in Clinical Trials	5	Target Synonym	Protein F，F，Fusion glycoprotein F0
Highest Development Stage	Approved

English Name	Respiratory syncytial virus F protein
Target Synonym	Protein F，F，Fusion glycoprotein F0
Approved Drugs	3
Drugs in Clinical Trials	5
Highest Development Stage	Approved

Fusion glycoprotein F0 Product List

Product Category
Antibody (2)Protein (1)
Product Status
Launched (3)
Species
Mouse (2)Mumps virus (1)
Tag
- (2)His Tag & Avi Tag (1)
Conjugate
Unconjugated (2)Biotin-labeled (1)

Cat. No.	Species	Host	Product Description
RSF-MY2092	Mouse	HEK293	Monoclonal Anti-Mumps virus Fusion glycoprotein F0 Antibody, Human IgG1 (5A3) (MALS verified)
RSF-MY2093	Mouse	HEK293	Monoclonal Anti-Mumps virus Fusion glycoprotein F0 Antibody, Human IgG1 (8F8) (MALS verified)
RSF-M82E3	Mumps virus	HEK293	Biotinylated Mumps virus (strain Miyahara vaccine) (MuV) Fusion glycoprotein F0 Protein, His,Avitag™

Total: 3

Fusion glycoprotein F0 Background

The two surface glycoproteins of the mumps virus are the hemagglutinin-neuraminidase (HN) and Fusion proteins. These glycoproteins are essential for viral entry to host cells, and the spread of newly formed virions. The mumps fusion protein (F) is a 538-amino acid, class one fusion surface glycoprotein. It is responsible for the membrane fusion of virus and host cell. The un-cleaved protein has three hydrophobic regions: an amino-terminal signal peptide, an amino terminal region of F1 and the carboxyl-terminal membrane domain. This protein starts as a precursor molecule (F0), and is then cleaved into the active protein by the recognition of a R-X-L/R-R motif by a host endoprotease (furin). The F protein contains two disulfide-linked polypeptides (F1 and F2).

Fusion glycoprotein F0 Synonyms

Fusion glycoprotein F0

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
CPI-RSV-F Vaccine	BLB-201	Phase 2 Clinical	Blue Lake Biotechnology Inc	Respiratory Syncytial Virus Infections	Details
RSV vaccine (Vaxart)		Phase 1 Clinical	Vaxart Biosciences Inc	Respiratory Syncytial Virus Infections	Details
GR-2102	GR2102; GR-2102	Phase 1 Clinical	Chongqing Genrix Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd	Respiratory Syncytial Virus Infections	Details
Palivizumab biosimilar (mAbxience)	MB-05	Phase 1 Clinical	Mabxience Sa		Details
RSM-01		Phase 1 Clinical	Bill & Melinda Gates Medical Research Institute	Respiratory Syncytial Virus Infections	Details

Marketed Drug Information

English Name	Research Code	Highest Development Stage	Company	Earliest Brand Name	Earliest Approval Country	Earliest Indication	Earliest Approval Company	Earliest Approval Date	Indication	Clinical Trial
Nirsevimab	Anti-RSV-mAb-D25; SP-0232; MEDI-8897; Anti-RSV MAb-YTE	Approved	Aimm Therapeutics, MedImmune Inc, Sanofi	Beyfortus, 乐唯初	EU	Respiratory Syncytial Virus Infections	Sanofi Winthrop Industrie SA	2022-10-31	Lower Respiratory Tract Infections; Respiratory Syncytial Virus Infections	Details
Palivizumab	ABT-315; MEDI-493	Approved	Abbvie Inc, Medimmune Llc	Synagis	United States	Respiratory Syncytial Virus Infections	Swedish Orphan Biovitrum Ab (Publ)	1998-06-19	Bronchiolitis; Bronchopulmonary Dysplasia; Heart Defects, Congenital; Infant, Premature, Diseases; Premature Birth; Respiratory Syncytial Virus Infections	Details
Respiratory syncytial virus immune globulin	RSV-IGIV	Approved	Medimmune	RespiGam	United States	Respiratory Syncytial Virus Infections	null	1996-01-01	Respiratory Syncytial Virus Infections	Details